Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506003 | 1.00 | CCKBR (0.52) | CCKBRCCKAR | |
| SCHEMBL1506002 | 1.00 | CCKBR (0.52) | CCKBRCCKAR | |
| SCHEMBL6521829 | 0.94 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL6519843 | 0.94 | CCKBR (0.56) | CCKBRCCKAR | |
| SCHEMBL6519450 | 0.94 | CCKBR (0.56) | CCKBRCCKAR | |
| SCHEMBL1505901 | 0.94 | CCKBR (0.56) | CCKBRCCKAR | |
| SCHEMBL1506092 | 0.90 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL16498423 | 0.90 | CCKBR (0.51) | CCKBRCCKAR | |
| SCHEMBL1506005 | 0.89 | CCKBR (0.56) | CCKBRCCKAR | |
| SCHEMBL16499162 | 0.89 | CCKBR (0.50) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | CCKBR 180/4885CCKAR 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.